Sar156597 (act14604) (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02921971 (ClinicalTrials.gov) | November 23, 2016 | 30/9/2016 | Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis | Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study | Systemic Sclerosis | Drug: SAR156597 (ACT14604);Drug: Placebo | Sanofi | NULL | Completed | 18 Years | N/A | All | 97 | Phase 2 | United States;Argentina;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;Austria |